CYDY.US Cytodyn Inc

Healthcare Biotechnology USA Stocks
0.2500 USD
Close of Nov 13, 2026
0.1800 0.4000
Market cap
USD 367M
P/E
-
P/B
1,066.03x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending May 2026.

Is CYDY.US undervalued?

Graham number

The Graham number of Cytodyn Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cytodyn Inc fundamental analysis

No fundamental analysis for Cytodyn Inc yet.

Cytodyn Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cytodyn Inc

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly know…

Full company profile